About: Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 09 January 2020

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) artículu científicu espublizáu en xineru de 2020 (ast) article scientifique publié en 2020 (fr) im Januar 2020 veröffentlichter wissenschaftlicher Artikel (de) наукова стаття, опублікована 9 січня 2020 (uk) scientific article published on 09 January 2020 (en)
publication date	wds:Q92572717-63DCC735-A12C-433E-8012-572D54390074
publication date	2020-01-09 00:00:00Z (xsd:dateTime)
cites work	wds:Q92572717-0126B3EA-816F-4073-BC6B-576D5B6D2E09 wds:Q92572717-056AA941-073B-428E-9E68-24862C7A6578 wds:Q92572717-155CFC22-FF7D-4361-AB57-B120ABE0F666 wds:Q92572717-1FF98438-9C02-4860-B0D5-84AECBD551B8 wds:Q92572717-239BA419-8F7F-4841-8CF3-DF1696647AA3 wds:Q92572717-458DD5B9-6F07-415D-BB2E-5EA042D7F042 wds:Q92572717-51521ED9-4C94-402F-9BE1-436B516DBDB5 wds:Q92572717-5BC3614C-95B5-4584-8C96-B1CE45CC133E wds:Q92572717-64D57370-BC41-4CA1-8E64-1BA8CF1A359A wds:Q92572717-679FA0F0-BDD9-407F-8ABA-44432103E2D2 wds:Q92572717-7CDAA71B-D782-47A9-93E7-B7FCDCA76BDF wds:Q92572717-7F085DD0-394D-49AE-ACC3-B49349F2AF2B wds:Q92572717-8128889E-D109-44F2-8564-27353AECFB1B wds:Q92572717-83CDF9E2-2825-45BC-9C58-79102083D7A0 wds:Q92572717-914CE9C4-2456-4F79-B493-5E80B4BAA9CD wds:Q92572717-BDF32A16-8781-4F4F-BBC1-BB85248A5A5E wds:Q92572717-C29AA904-1ED9-4AE3-857F-AFC8FF776217 wds:Q92572717-C4D15517-FCAF-44E2-9C5F-AEB882ACD72A wds:Q92572717-C792A14D-7C5D-46A2-B1C9-FE1BB130C206 wds:Q92572717-CB86A8BC-9A16-4CB9-97E3-DC0F2A8EEBE2 wds:Q92572717-EE3ECE38-04CD-480C-B9AA-AB5BA1401639 wds:Q92572717-F26F29F8-2B3C-4913-85E4-B67CB81353B3 wds:Q92572717-F97EB0D4-A38C-49FF-B7DA-502BE8F5BB50 wds:Q92572717-F98D7E6A-0F20-49BC-94BF-C362B981B8F7
cites work	Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease† A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
author name string	wds:Q92572717-18518822-3055-4C10-8F89-92CD59A22608 wds:Q92572717-19B50D1D-5CF9-4671-BD1A-7EF47103644E wds:Q92572717-1E2207AC-AC58-4E74-A88F-006A949ACB10 wds:Q92572717-3C20C6D0-D1A4-494D-803D-0C0EF8C668A4 wds:Q92572717-4240C13D-129B-407F-94B3-5F6809DB76B4 wds:Q92572717-616A86B7-253D-44D8-A3C2-46FED8CDC701 wds:Q92572717-86FA6893-1099-4A71-BEA5-B913EDEEA06D wds:Q92572717-9286C790-C79B-439B-9531-A39FD6D3D0E7 wds:Q92572717-986E00E6-5068-4CE1-8618-909AC0D77080 wds:Q92572717-D175AE6F-84D0-4118-B1F9-13B26F2257D7 wds:Q92572717-D20AF41E-FCB9-4F9A-BE02-3DE038DD35BB wds:Q92572717-D6F04A92-618D-4AC2-925E-D20F77941295 wds:Q92572717-E9B98E25-3023-43D5-A944-42E5FB2F8567 wds:Q92572717-FA7EE226-1314-4ED6-BB24-616079DA0C4F
author name string	Minako Mori Kazuto Nakamura Mototsugu Shimokawa Takahiro Arai Masakazu Abe Nobuhiro Kado Akio Suzuki Michiru Sakurai Yukiyoshi Fujita Motoki Takenaka Ryuichi Shimaoka Saki Murase Senri Yamamoto Yoh Hayasaki
rdfs:label	Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study (en) Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study (nl)
skos:prefLabel	Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study (en) Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study (nl)
name	Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study (en) Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study (nl)
author	wds:Q92572717-840A4BA7-6FD1-4A63-A066-3B18ED506189 wds:Q92572717-ED620D8A-702E-411B-8ABE-7DB9BA3E518B
author	Hirotoshi Iihara Ken-ichirou Morishige
title	wds:Q92572717-49976B4C-871B-4FBB-93C5-57550DA0D448
title	Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study (en)
page(s)	wds:Q92572717-04343B08-1096-4398-BD83-C8B36E1BCE21
page(s)	629-635
instance of	wds:Q92572717-D7D493FE-CA83-415D-8300-6EE88F516657

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software